Multi-omics Characterization of Pancreatic Neuroendocrine Tumors and Carcinomas

NCT05234450 | Unknown

• 1 other identifier: 7561
• Study Type: observational
• Target: 300
• Locations: 1 country
• Sites: 1

Brief Summary

In this work, the investigators count through the integrated multi-omics analysis to identify different tumor subgroups in pancreatic neuroendocrine tumors and carcinomas regardless of their grade and stage. To achieve this, they will resort to the use of next-generation sequencing approaches (RNAseq, then use of MCP Counter for the absolute quantification of the eight populations of immune cells in the tumor microenvironment), alterations in epigenetics with study of the methylome by MeDIP, ChIPseq, telomere (ALT) study, as well as correlation with peripheral blood neutrophil to lymphocyte ratio and immunohistochemistry data such as Ki67, p53, Rb, DAXX, ATRX, PDL1, immune cell labeling. This will be done on frozen or paraffin material. This work will provide a more complete biological picture of pancreatic neuroendocrine tumors and carcinomas.

Conditions

Cancer of Pancreas

Keywords

Cancer of Pancreas; Neuroendocrine Tumors; Carcinoma; Neuroendocrine

Outcome Measures

Primary Outcomes (1)

• Establishment of the number of tumor subgroups by integrating data from all multi-omics analyses

  1 month

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patient (≥18 years old) with histologically confirmed tumor or neuroendocrine carcinoma of the pancreas

You may qualify if:

• Adult patient (≥18 years old)
• Subject with histologically confirmed tumor or neuroendocrine carcinoma of the pancreas
• Subject with tumors or neuroendocrine carcinoma of the pancreas regardless of the stage of the disease
• Supported at the University Hospitals of Strasbourg between 01/01/2008 and 01/09/2019
• Near therapeutic blood count available (less than 6 months)
• Availability of frozen and/or paraffin tumor material
• Patients who have already given their consent for their biological resources to be kept at the CRB or in the anatomopathology department of the HUS, and subsequently reused, as well as the anonymous data associated with them, for scientific research purposes.

You may not qualify if:

• Opposition of the patient to participate in the study
• Diagnosis other than pancreatic neuroendocrine tumor
• Impossibility of giving informed information to the subject
• Patient under judicial protection En savoir plus sur ce texte sourceVous devez indiquer le texte source pour obtenir des informations supplémentaires Envoyer des commentaires Panneaux latéraux

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service d'Oncologie - CHU de Strasbourg - France

Strasbourg, 67091, France

RECRUITING

MeSH Terms

Conditions

Pancreatic Neoplasms; Neuroendocrine Tumors; Carcinoma

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Digestive System Diseases; Pancreatic Diseases; Endocrine System Diseases; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms, Nerve Tissue; Neoplasms, Glandular and Epithelial

Study Officials

• Gabriel MALOUF, MD, PhD

  Service d'Oncologie - CHU de Strasbourg - France

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Gabriel MALOUF, MD, PhD

CONTACT

33 3 88 11 51 41; malouf.gabriel@chru-strasbourg.fr

Saïd CHAYER, PhD, HDR

CONTACT

said.chayer@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 31, 2022
• First Posted: February 10, 2022
• Study Start: December 1, 2021
• Primary Completion: June 1, 2022
• Study Completion: June 30, 2022
• Last Updated: February 10, 2022

Record last verified: 2022-01

Locations

FR (1)